Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Morphologic Characteristics Seen in High-grade Serous Ovarian Carcinoma Metastases in Postneoadjuvant Chemotherapy Resections.
Int J Gynecol Pathol
December 2024
Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School. Boston, MA. USA.
The morphologic features of metastatic high-grade serous ovarian carcinoma (HGSOC) after neoadjuvant chemotherapy have not been described. We conducted a 1-year retrospective, single-institution review of pretreatment biopsy and posttreatment metastases in cases of HGSOC treated with neoadjuvant chemotherapy. Two gynecologic pathologists and 1 pathology resident reviewed 11 cases looking for 6 morphologic features.
View Article and Find Full Text PDFFertility-sparing surgery versus radical surgery for micropapillary serous borderline ovarian tumours: a systematic review protocol.
BMJ Open
November 2024
Department of Obstetrics and Gynecology, Xuanwu Hospital Capital Medical University, Beijing, China
Introduction: Micropapillary serous borderline ovarian tumours (MP-SBOTs) are an aggressive subtype of serous borderline ovarian tumours (SBOTs). Surgery is the mainstay of treatment. Radical surgery (RS, including debulking) is an alternative.
View Article and Find Full Text PDFMicropapillary pattern in serous borderline ovarian tumor and the risk of extraovarian localization of low-grade serous carcinoma ('invasive implants'): A systematic review and meta-analysis.
Pathol Res Pract
December 2024
Pathology Unit, Department of Woman and Child's Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Department of Life Sciences and Public Health, Catholic University of Sacred Heart, Rome, Italy.
In serous borderline ovarian tumor (SBOT), a micropapillary (MP) pattern has been considered analogous to intraepithelial low-grade serous carcinoma (LGSC). On this account, it is reasonable to hypothesize that MP-SBOT is more likely to be associated with extraovarian LGSC localizations (also referred to as 'invasive implants') compared to conventional SBOT. The aim of this study was to investigate the potential association between a MP pattern and invasive implants in SBOT.
View Article and Find Full Text PDF[Oncological and reproductive outcomes after fertility-sparing surgery in patients with stage Ⅱ-Ⅲ borderline ovarian tumor].
Zhonghua Fu Chan Ke Za Zhi
September 2024
Department of Gynecology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Article Synopsis
- The study evaluated oncological and reproductive outcomes of women aged 40 and younger who underwent fertility-sparing surgery for stage II or III borderline ovarian tumors (BOT) at a specific hospital between 2011 and 2023.
- A total of 79 patients were treated, with an average age of 27.5 years, and a follow-up period averaging 58 months, revealing a 30% recurrence rate and a small number of deaths.
- Prognostic risk factors for worse outcomes included having a mucinous tumor, a maximum tumor diameter over 13.15 cm, FIGO stage III, and certain invasive characteristics.
HER2 Status in Low-grade Serous Ovarian Tumors.
Int J Gynecol Pathol
July 2024
Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Using immunohistochemistry, we examined a large cohort of 135 ovarian tumors, made up of 96 low-grade serous carcinomas (LGSCs) and 39 serous borderline tumors (micropapillary variant, mSBT), with the aim of exploring their HER2 status (overexpression). We followed with comprehensive genomic analyses on this sample set from our previous study, which revealed HER2 mutation in 5% (4/75) of LGSC and 10% (3/29) of mSBT. No cases were evaluated as HER2-positive, but 6 LGSCs and 1 mSBT were scored as HER2 1+, and 2 LGSCs and 1 mSBT showed the so-called HER2 "ultra-low" phenotype.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!